WASHINGTON: Merck's anti-Covid pill remains "active" against the Omicron variant, the US drugmaker said Friday (Jan 28), citing results from six laboratory studies.
The oral treatment, called molnupiravir, is taken within five days of symptom onset and was shown in a pre-Omicron trial of 1,400 participants to reduce Covid hospitalisations and deaths by 30 percent among at-risk people.
Already a subscriber? Log in
Play, subscribe and stand a chance to win prizes worth over RM39,000! T&C applies.
Cancel anytime. Ad-free. Unlimited access with perks.
